# NCT06712316 (NCT06712316)

> Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06712316
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pumitamig; Pembrolizumab; Carboplatin; Pemetrexed; Paclitaxel
- Enrollment: 1580
- Primary outcome: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs
- Primary outcome: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)
- Primary outcome: Phase 2 - Objective response rate (ORR)
- Primary outcome: Phase 2 - Best percentage change from baseline in tumor size
- Primary outcome: Phase 3 - Progression free survival (PFS) assessed by BICR

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06712316